DAP-kinase and therapy-related AML
. | Unmethylated, n = 15 . | Methylated, n = 14 . | P . |
|---|---|---|---|
| Age, y, mean ± SEM | 51.9 ± 3.6 | 65.6 ± 2.2 | .003 |
| Sex, F/M | 12/3 | 8/6 | .2 |
| Morphology | .7 | ||
| No MDS | 8 | 6 | |
| With MDS | 4 | 5 | |
| Primary tumor, n (%) | .3 | ||
| Breast | 7 (70) | 3 (30) | |
| Lymphoproliferative | 4 (40) | 6 (60) | |
| Others | 4 (44.4) | 5 (55.6) | |
| Time from primary tumor, y, mean ± SEM | 7.9 ± 1.8 | 4.4 ± 0.7 | .09 |
| Treatment, n (%) | — | ||
| Chemotherapy | 11 (52) | 10 (48) | |
| Alkylating agents | 7 (50) | 7 (50) | |
| Topo inhibitors | 6 (66.6) | 3 (33.3) | |
| Alkylating agents + topo inhibitors | 5 (71.4) | 2 (28.6) | |
| Chemotherapy + radiotherapy | 2 (40) | 3 (60) | |
| Radiotherapy alone | 3 (43) | 4 (57) |
. | Unmethylated, n = 15 . | Methylated, n = 14 . | P . |
|---|---|---|---|
| Age, y, mean ± SEM | 51.9 ± 3.6 | 65.6 ± 2.2 | .003 |
| Sex, F/M | 12/3 | 8/6 | .2 |
| Morphology | .7 | ||
| No MDS | 8 | 6 | |
| With MDS | 4 | 5 | |
| Primary tumor, n (%) | .3 | ||
| Breast | 7 (70) | 3 (30) | |
| Lymphoproliferative | 4 (40) | 6 (60) | |
| Others | 4 (44.4) | 5 (55.6) | |
| Time from primary tumor, y, mean ± SEM | 7.9 ± 1.8 | 4.4 ± 0.7 | .09 |
| Treatment, n (%) | — | ||
| Chemotherapy | 11 (52) | 10 (48) | |
| Alkylating agents | 7 (50) | 7 (50) | |
| Topo inhibitors | 6 (66.6) | 3 (33.3) | |
| Alkylating agents + topo inhibitors | 5 (71.4) | 2 (28.6) | |
| Chemotherapy + radiotherapy | 2 (40) | 3 (60) | |
| Radiotherapy alone | 3 (43) | 4 (57) |
Morphology subpopulations were as follows: no MDS, n = 14; and with MDS, n = 9. Primary tumor subpopulations evaluated were as follows: breast, n = 10; lymphoproliferative, n = 10; and others, n = 9.
— indicates not calculated.